Oxford Pharmascience Group Share News (OXP)

LONDON (Alliance News) - Oxford Pharmascience Group PLC on Thursday said it has started dosing in its second pilot clinical study of its OXPzero Ibuprofen.

OXP001, the product being tested, is a chewable, 400mg ibuprofen tablet that is expected to reduce the risk of gastro-intestinal irritation from the ibuprofen and to taste-mask its bitter taste using OXPzero technology.

"We are pleased to have overcome the significant technical hurdles in the development of an immediate release, chewable, taste masked OXPzero Ibuprofen tablet. Progressing this optimised OXP001 product to the clinic will provide the data to confirm further the benefits of the OXPzero technology including reduced GI irritation," said Chief Executive Marcelo Bravo.

Shares in the company were down 1.2% to 10.00 pence on Thursday.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2015 Alliance News Limited. All Rights Reserved.